Concepedia

Kerri Lasky

KL

Statistics

Publications

6

Citations

268

H-Index

6

Active since

2011

Affiliations

Incyte (United States)(Current)

Takeda (United States)

Millennium Engineering and Integration (United States)

Kerri Lasky is an author at Incyte (United States) specializing in oncology, pharmacology, and medicine.

Publications per year

2011–2020

6

Publications

6

Characterization of human cancer xenografts in humanized mice

Jonathan Rios‐Doria, Christina Stevens, Christopher Maddage et al. · Journal for ImmunoTherapy of Cancer · 2020 · 74 citations · Full text

, , +17

Plk1 Inhibition Causes Post-Mitotic DNA Damage and Senescence in a Range of Human Tumor Cell Lines

Denise L. Driscoll, Arijit Chakravarty, Doug Bowman et al. · PLoS ONE · 2014 · 62 citations · Full text

, , +17

Discovery of a Potent and Orally Bioavailable Benzolactam-Derived Inhibitor of Polo-Like Kinase 1 (MLN0905)

Matthew O. Duffey, Tricia J. Vos, Ruth Adams et al. · Journal of Medicinal Chemistry · 2011 · 56 citations · Full text

, , +14

A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity

Jonathan Rios‐Doria, Margaret Favata, Kerri Lasky et al. · Frontiers in Oncology · 2020 · 42 citations · Full text

, , +17

MLN0905, a Small-Molecule <i>PLK1</i> Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma

Judy Quiju Shi, Kerri Lasky, Vaishali Shinde et al. · Molecular Cancer Therapeutics · 2012 · 21 citations

, , +15

1–5 of 6